Medical Condition News

RSS

Novel investigational drug may help restore cardiac function after heart failure

Cimaglermin, a new experimental drug, may help restore cardiac function after heart failure, according to a first-in-man study published today in JACC: Basic to Translational Science.

27 Dec 2016

New research points to lncRNA's key role in helping control cellular processes

Scientific research over the past decade has concentrated almost exclusively on the 2 percent of the genome's protein coding regions, virtually ignoring the other 98 percent, a vast universe of non-coding genetic material previously dismissed as nothing more than 'junk.'

27 Dec 2016

People with increased risk for heart disease could more likely have shoulder problems

After all the lifting, hauling and wrapping, worn out gift givers may blame the season's physical strain for any shoulder soreness they are feeling.

27 Dec 2016

New discovery could lead to effective drugs to prevent excessive lymphatic growth in cancer

Cancer cells spread to other sites in the body through promoting the growth of new 'roads' to travel on.

27 Dec 2016

MMJ Labs to launch new wearable pain therapy device at runDisney Health and Fitness Expo

MMJ Labs, LLC, industry leaders in non-invasive pain relief, will debut their newest product, VibraCool® Massaging Ice Therapy, at the runDisney Health and Fitness Expo in Orlando, FL.

26 Dec 2016

Saint Louis University geriatrician urges older patients to talk to doctors about too many pills

If you're 65 or older and taking more than four medications, resolve to talk to your doctor about doing a New Year's triage to make sure too many pills aren't making you sick, advises Milta Little, D.O., associate professor of geriatrics at Saint Louis University.

26 Dec 2016

Researchers develop synthetic cardiac stem cells that offer therapeutic benefits

Researchers from North Carolina State University, the University of North Carolina at Chapel Hill and First Affiliated Hospital of Zhengzhou University have developed a synthetic version of a cardiac stem cell.

26 Dec 2016

Gulf Breeze Recovery underscores importance of high-quality programs for treating opioid addiction

As opioid addiction hits record highs, Gulf Breeze Recovery, a Florida-based addiction recovery center, stresses the importance of high-quality, successful programs for treating addiction.

26 Dec 2016

Four-year Johns Hopkins program provides efficient, less expensive care for patients in East Baltimore

When people with chronic health problems couldn't get around town to their doctors' appointments, a four-year Johns Hopkins program brought the appointments to them.

25 Dec 2016

Sight Sciences receives Health Canada approval for TRAB 360 Trabeculotomy System

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received Health Canada approval for the TRAB 360 Trabeculotomy System.

23 Dec 2016

OTC medical device receives CE Mark approval to treat pain linked to fibromyalgia

AVACEN Medical announced its AVACEN 100, Class-IIa, OTC medical device has received the CE Mark approval to treat widespread pain associated with fibromyalgia.

23 Dec 2016

Study shows three-drug combination delays recurrence and lengthens life for myeloma patients

The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.

23 Dec 2016

DDF launches three grants to fund opportunities for gastric cancer research

Debbie's Dream Foundation: Curing Stomach Cancer, an international non-profit organization that raises awareness and funds for stomach cancer, launched three research grants totaling $300,000 for the 2016-2017 grant cycle.

23 Dec 2016

Inherited CD70 deficiency increases susceptibility to Epstein-Barr virus and EBV-related cancer

Investigators at the National Institutes of Health and international colleagues have identified a genetic immune disorder characterized by increased susceptibility and poor immune control of Epstein-Barr virus (EBV) and, in some cases, an EBV-associated cancer called Hodgkin's lymphoma.

23 Dec 2016

FDA approves first drug to treat children and adults with spinal muscular atrophy

The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

23 Dec 2016

Researchers find increase in heart attacks during Christmas holidays

University of Melbourne researchers have found an increase in heart attacks around the festive period may be due to more difficult access to hospitals, combined with stress, an excess of alcohol and a fatty diet.

23 Dec 2016

UCLA-led consortium receives $8.6 million NIH grant to map the heart's nervous system

A consortium directed by UCLA's Dr. Kalyanam Shivkumar has received a three-year, $8.6 million grant from the National Institutes of Health to map the heart's nervous system.

23 Dec 2016

UCLA-led research finds promising results for more personalized head and neck cancer treatment

Researchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.

23 Dec 2016

FDA approves Dexcom’s G5 Mobile CGM system for diabetes management

Dexcom, Inc., the leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that the U.S. Food and Drug Administration has approved its G5 Mobile CGM system as the first and only continuous glucose monitoring system that can be used to make daily diabetes treatment decisions without finger pricking.

23 Dec 2016

Cycle Pharmaceuticals receives license for IP on PARP inhibitor drugs for treating vascular disease

Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to CYCLE Pharmaceuticals.

23 Dec 2016

Medical Condition News

Novel investigational drug may help restore cardiac function after heart failure

New research points to lncRNA's key role in helping control cellular processes

People with increased risk for heart disease could more likely have shoulder problems

New discovery could lead to effective drugs to prevent excessive lymphatic growth in cancer

MMJ Labs to launch new wearable pain therapy device at runDisney Health and Fitness Expo

Saint Louis University geriatrician urges older patients to talk to doctors about too many pills

Researchers develop synthetic cardiac stem cells that offer therapeutic benefits

Gulf Breeze Recovery underscores importance of high-quality programs for treating opioid addiction

Four-year Johns Hopkins program provides efficient, less expensive care for patients in East Baltimore

Sight Sciences receives Health Canada approval for TRAB 360 Trabeculotomy System

OTC medical device receives CE Mark approval to treat pain linked to fibromyalgia

Study shows three-drug combination delays recurrence and lengthens life for myeloma patients

DDF launches three grants to fund opportunities for gastric cancer research

Inherited CD70 deficiency increases susceptibility to Epstein-Barr virus and EBV-related cancer

FDA approves first drug to treat children and adults with spinal muscular atrophy

Researchers find increase in heart attacks during Christmas holidays

UCLA-led consortium receives $8.6 million NIH grant to map the heart's nervous system

UCLA-led research finds promising results for more personalized head and neck cancer treatment

FDA approves Dexcom’s G5 Mobile CGM system for diabetes management

Cycle Pharmaceuticals receives license for IP on PARP inhibitor drugs for treating vascular disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News